Mortality Prediction Hidden in our Genome

26/02/2019

The success of hematopoietic stem cell transplant (HSCT) is influenced by many factors including HLA mismatches, variations in the major histocompatibility complex (MHC) region, minor histocompatibility targets of allorecognition, regulatory elements that affect gene expression and genetic variation that affects immune responses (Table 1, Table 2). The individual contribution...

Omixon to Sponsor EWIC 2019 Conference with Scientific Talk

11/02/2019

Omixon is proud to announce that we are one of the Silver Sponsors of the Annual EWIC 2019 Conference. Libor Kolesár (Senior Field Application Scientist) and Nina Lauterbach (Field Application Scientist) will announce improvements to the existing products and an interesting talk by Mette Christiansen from Aarhus University. Title of...

EWIC, March 14-16, 2019

11/02/2019

We are happy to announce that Omixon is one of the Silver Sponsors of this year’s EWIC Conference in Zagreb, Croatia. Title of our talk: “Donor selection for solid organ transplantation guided by NGS high resolution HLA typing in combination with PIRCHE “ Date: Friday, March 15, 2019 Time:...

THIS IS US: A Letter from CEO, Dr. Peter Meintjes

31/01/2019

Dear Customers and Friends of Omixon, Cue the emotion-grabbing drawn-out string music, cue the slow motion, zoomed-in camera shots focused on faces to capture the true depth of the feelings of the moment, and cue the hazy image filters that send you into the story telling time machine of...

Holotype HLA Validation on Illumina’s MiniSeq

31/01/2019

Introduction The Illumina NGS sequencing fleet includes instruments of different sample capacity. One of them is the MiniSeq – designed for laboratories with a small to medium sample throughput. Omixon’s Holotype HLA was initially developed and validated for Illumina’s MiSeq, as this is a commonly available instrument in clinical...